SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Commercial Services

People on the move

By Natalie Morrison , 09-Jan-2012
Last updated on 09-Jan-2012 at 13:02 GMT

Outsourcing-Pharma presents its weekly round-up of the latest appointments within the pharmaceutical industry, including news from Mylan, Aegate, and Intralinks.

Mylan has drafted in John Thievon as president of its respiratory and allergy drug manufacturing and development firm Dey Pharma.

His most recent position was as president and CEO of anti-infective products specialists Middlebrook Pharmaceuticals, which sold all of its assets to Victory Pharma in 2010.

Of his new appointment, Theivon said he was excited to expand Dey’s product offering.

Mylan president Heather Bresch added: “Dey has been and continues to be a very valuable asset and important growth driver for Mylan, evidenced by the strong performance of this business.

“John's appointment demonstrates our continued commitment to invest in Dey and strengthen what we have in place in order to support the continued success of this business into the future.”

Former director general of the Association of the British Pharmaceutical Industry (ABPI) Richard Barker will become Aegate’s new senior adviser.

Barker is currently director of the Centre for Accelerating Medical Innovations and serves as an advisor to a number of healthcare companies.

The authentication and traceability service provider also named Michael Peace as new CEO following the departure of Gary Noon. He joins the firm following a stint as head of Asia for Thomson Reuter’s Financial Markets business.

David Cooksey, chairman of Aegate said: “Michael's experience of building teams and businesses across multiple geographies and Richard's substantial pharmaceutical industry expertise will be invaluable, now that new European Legislation for falsified medicines has made it clear that patient safety systems such as Aegate's are going to become a legal requirement.”

Information exchange solutions provider IntraLinks has appointed Ronald Hovsepian as president and CEO.

Hovsepian, most recently president and CEO of Novell, will also serve on the company's board of directors.

Of his new role, he said he feels fortunate to join a talented team, adding: "IntraLinks is a cloud pioneer that invented one of the first and, in my opinion, the best platform to exchange mission-critical information with business partners beyond the firewall while still assuring enterprise-level security and compliance.”

Independent healthcare agency AbelsonTaylor has made changes to its senior management team.

Former account supervisors Shanika Bradley and Rich Campbell will both become senior account supervisors.

Bradley joined the firm nine years ago, and will continue her responsibilities for product launches related to lupus and epilepsy treatments.

Campbell will work on women’s health marketing, and will focus specifically on an osteoporosis drug for postmenopausal women. He has been with the company for 10 years.

Once planning and research director at Chicago-based Legacy Marketing Partners, Inbal Shohat-Pawlowski is AbelsonTaylor’s latest new hire. She will become senior account planner.

AAIPharma has hired Kevin Flanagan as VP of packaging services.

Flanagan joins the firm from Compass Pharma Services, a pharmaceutical contract packaging firm, where he served as president.

In his new role, he will oversee the company's packaging and distribution functions at its Wilmington headquarters.

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE

All Gallery

People on the Move

People on the Move

Regulatory experts dominate this week's column on who's who in pharmaceutical outsourcing.

On the move: CRISPR experts, CFOs and PM Society awards finalists

On the move: CRISPR experts, CFOs and PM Society awards finalists

All the latest hires in our weekly column.

Who's going places?

Who's going places?

The latest hires in pharmaceutical outsourcing in this week's column.